

SCIENTIFIC REPORTS

OPEN

Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population

Rana Moustafa Al Adawi¹, Zainab Jassim¹, Dina Elgaily¹, Hani Abdelaziz², Bhagya Sree³ & Mohamed Izham Mohamed Ibrahim⁴

The effectiveness of dapagliflozin in the management of type-2 diabetes mellitus (T2-DM) is an essential issue for establishing a basis for prescribing dapagliflozin. This study aimed to assess the effectiveness of dapagliflozin in combination with other hypoglycemic agents (OHAs) in reducing glycated hemoglobin (HbA1c) and fasting blood glucose (FBG) at 3, 6, 9 and 12 months. This retrospective observational study included all patients who visited the endocrine clinics at Hamad Medical Corporation (HMC) and were treated with dapagliflozin. Demographics and laboratory data were obtained retrospectively from computerized patient medical profiles (eMR-viewer). The main outcome measures were the differences in HbA1c and FBG from baseline at different months. Eighty-one Qatari patients were found to have received dapagliflozin during the study period; 72% of them ($n = 58$) were males, with a mean age of 57.0 ± 9.0 years and a mean baseline HbA1c of $9.0 \pm 1.4\%$. Administration of dapagliflozin as an add-on therapy was found to decrease HbA1c significantly by 0.8 percentage point after 6 months ($P = 0.006$) and by 1.5 percentage point after 12 months ($P = 0.062$). FBG was significantly reduced at 6 months and 9 months ($P = 0.001$ and $P = 0.03$, respectively). Dapagliflozin effectively reduced the HbA1c level and FBG when used in combination with other OHAs or insulin within 6 to 12 months.

Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, a new class of oral antihyperglycemic drugs with an innovative mechanism of action, and is the second SGLT2 inhibitor to be approved by the Food and Drug Administration of the United States of America (FDA). Managing type 2-diabetes mellitus (T2-DM) with effective and tolerable oral agents will eventually decrease the devastating complications associated with uncontrolled T2-DM and ultimately improve quality of life. In 1990, a novel class of drugs to treat T2-DM with glucose urea was developed but was limited by poor bioavailability due to poor absorption as well as rapid degradation¹⁻³. This discovery opened the gate for a promising group of drugs for the treatment of T2-DM, SGLT2 inhibitors, and this group includes canagliflozin, which became the first SGLT2 inhibitor approved by the FDA, followed by dapagliflozin, which was approved by the FDA on January 8, 2014^{4,5}.

SGLT2 localizes almost exclusively to the kidney proximal tubules, where it reabsorbs most of the ~180 g of glucose that is filtered through the glomeruli each day⁶. In diabetic patients, the SGLT2 cotransporters are significantly upregulated, increasing glucose reabsorption and leading to glucose conservation and prolonged hyperglycemia. Dapagliflozin is a highly selective and reversible inhibitor of SGLT2 that acts by inhibiting tubular reabsorption of up to half of the glucose filtered by SGLT2 located at segments 1 and 2 in the proximal renal tubule, resulting in a dose-dependent increase in urinary glucose excretion and ultimately, an improvement in glycemic parameters⁷⁻¹⁰. Its C-aryl glucoside-derived chemical structure provides dapagliflozin with a prolonged pharmacokinetic half-life as well as a nearly 3000-fold selectivity for SGLT2 versus SGLT1, making it possible to administer dapagliflozin in an unmodified oral form without affecting SGLT-1-mediated glucose transport in other tissues¹¹⁻¹⁴.

¹Pharmacy Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar. ²Pharmacy Department, Al Wakra Hospital, Hamad Medical Corporation, Doha, Qatar. ³Women Wellness and Research Center, Hamad Medical Corporation, Doha, Qatar. ⁴Social & Administrative Pharmacy, College of Pharmacy Qatar University, PO Box 2713, Doha, Qatar. Correspondence and requests for materials should be addressed to M.I.M.I. (email: mohamedizham@qu.edu.qa)

Demographics	n (%)	Mean (SD)
Gender		
Male	58 (72.0)	
Female	23 (28.0)	
Nationality		
Qatari	81 (100)	
non-Qatari	0 (0)	
Age		58 (8.6)
HbA1c		9.2 (1.4)
FBG		11 (4.0)
Co-medications		
Metformin	53 (65.0)	
Pioglitazone	5 (6.2)	
Gliclazide	23 (28.4)	
Glimepiride	15 (18.5)	
Glibenclamide	1 (1.2)	
Repaglinide	1 (1.2)	
Acarbose	1 (1.2)	
Insulin	36 (51.9)	
Vildagliptin	6 (7.4)	
Liraglutide	16 (19.9)	

Table 1. The demographic and clinical characteristics of patients at baseline.

This mechanism of action provides us with a valuable clue: dapagliflozin does not act through increasing insulin secretion or decreasing insulin receptor resistance, and thus, commencing therapy with this group of agents neither causes hypoglycemia nor depends on the duration of T2-DM. It can be initiated as monotherapy in newly diagnosed patients or in combination with other oral agents or insulin in patients with long-standing diabetes^{15,16}. However, the glucosuria induced by SGLT-2 inhibition might be attributed to hypoglycemia, UTIs, or genital infections¹⁷.

The efficacy of this novel group of medications requires extensive evaluation in different populations and with different regimens to establish the best practice for managing T2-DM^{18,19}. Many studies have evaluated SGLT2 inhibitors and confirmed the efficacy of dapagliflozin. Some studies demonstrated its effectiveness as monotherapy for newly diagnosed patients with T2-DM^{13,20–24}. Other groups of studies asserted its effectiveness in combination with other oral hypoglycemic agents^{19,25–28}. Moreover, when dapagliflozin was used in conjunction with insulin, studies reported the same level of efficacy with an additional benefit of decreasing insulin demand^{28–30}. Of note, dapagliflozin efficacy was well established over a wide range of populations, predominantly in Western populations. Yang *et al.* found that dapagliflozin as an add-on to insulin, with or without oral antidiabetic drugs (OADs) in Asian patients, significantly improved glycemic control³¹. However, to date, there is very few study that has examined the effectiveness of this group of medications in a Middle Eastern population, which has different genetic characteristics^{20,32,33} in addition to unique demographic, culture and lifestyle characteristics^{15,34–38}. All these variables may alter the response to SGLT2 inhibitors in general and specifically dapagliflozin.

This study aims to assess the effectiveness of dapagliflozin in the management of T2-DM in combination with other hypoglycemic agents (OHAs) or insulin, in terms of improving HbA1c and fasting blood glucose, among diabetic patients in Qatar. Almost all medicines in Qatar are imported, and the use of the brand originator is high. Thus, establishing evidence of the effectiveness of each medicine in the formulary is important. The results of this study will establish the efficacy of dapagliflozin in the management of T2-DM in Qatar in particular and the Middle East in general.

Results

Patient's profile. All eighty-one patients were Qataris with a mean age of 57 ± 9 years; of the patients, 72% were male. The mean HbA1c and fasting blood glucose at baseline were $9.2 \pm 1.4\%$ and 11 ± 4 mmol/L, respectively (Table 1).

Common diabetic treatment combinations. In this study, all patients received dapagliflozin as an add-on therapy in combination with standard diabetic treatment. They were divided into 4 treatment groups based on the most common combinations, and their baseline readings for HbA1c and fasting blood glucose (FBG) were equivalent ($p = 0.13$ and $p = 0.67$, respectively) (Table 2).

HbA1c and FBG levels at the follow-up period. In the follow-up period, repeated measures ANOVA was used to evaluate the difference in HbA1c and FBG following treatment with dapagliflozin. Only values from the 3- and 6-month follow-ups were included, as the number of patients who had data at all time points was very small. Although the overall p-values for the changes in HbA1c and FBG from baseline were significant ($p = 0.026$ & $p = 0.013$, respectively) (Table 3), the HbA1c value was significantly lowered from the baseline starting only at the 6-month follow-up ($p = 0.045$). Similarly, FBG began to decrease significantly at 6 months ($p = 0.019$).

Treatments groups: N (%)	Medications	A1c (%) at baseline Mean (sd)	FBG (mmol/L) at baseline Mean (sd)
Group 1: 16 (19.8)	Dapagliflozin + Metformin + Sulfonylureas (SUs) +/- DDP4i	9.2	11.8
Group 2: 27 (33.3)	Dapagliflozin + Metformin + DDP4i +/- Insulin	9.9	9.3
Group 3: 10 (12.3)	Dapagliflozin + Insulin + others	10.7	13.6
Group 4: 28 (34.6)	Other combinations Dapagliflozin + (Acarbose, Repaglinide, Liraglutide or Pioglitazone)	9.6	12.6

Table 2. The common diabetic treatment combinations.

Outcome measures	Baseline (mean/sd)	At 3 months (mean/sd)	At 6 months (mean/sd)	p value
HbA1c*	9.8 ± 0.4%	9.2 ± 0.35%	8.8 ± 0.27%	0.026
FBG**	11.4 ± 3.6 mmol/L	9.8 ± 4 mmol/L	8.5 ± 2 mmol/L	0.013

Table 3. HbA1c and FBG levels at baseline and 3 & 6 months posttreatment. *HbA1c baseline to 3 months; p = 0.48. **FBG baseline to 3 months; p = 0.63. HbA1c baseline to 6 months; p = **0.045**. FBG baseline to 6 months; p = **0.019**. HbA1c 3 months to 6 months; p = 0.45. FBG 3 months to 6 months; p = 0.311.

Treatment group	Baseline HbA1c (%)	After 3 months	After 6 months*	After 9 months	After 12 months	P value
Group 1	9.2 (0.64)	8.8 (1.7)	8.4 (1.3)	8.1 (1.2)	8.2 (1.4)	>0.05
Group 2	9.9 (1.6)	8.5 (1.0)	8.8 (1.6)	7.5 (1.7)	7.5 (2.0)	>0.05
Group 3	10.8 (3.2)	9.2 (0.3)	9.7 (0.7)	9.1 (1.3)	8.5 (1.0)	>0.05
Group 4	9.6 (1.3)	9.8 (1.6)	8.5 (0.6)	7.5 (1.0)	7.9 (1.1)	>0.05

Table 4. The change in HbA1c from baseline among the different treatment groups. Baseline to 6 months between-groups change in HbA1c (P = 0.9)*.

Treatment group	Baseline FBG (mmol/L)	After 3 months	After 6 months*	After 9 months	After 12 months	P value
Group 1	11.4 (3.2)	12.2 (4.5)	8.8 (1.3)	8.3 (0.6)	9.4 (1.8)	>0.05
Group 2	9.7 (2.6)	8.0 (3.1)	8.1 (1.8)	8.6 (0.8)	7.1 (2.1)	>0.05
Group 3	11.9 (4.0)	10.0 (3.7)	10.5 (1.5)	5.9 (0.9)	7.2 (0.07)	>0.05
Group 4	12.2 (4.9)	10.0 (3.2)	7.7 (1.4)	9.7 (1.3)	8.3 (0.9)	>0.05

Table 5. The change in fasting blood glucose (FBG) from baseline among the different treatment groups. Baseline to 6 months between-groups change in FBG (P = 0.8)**.

Changes in HbA1c and FBG from baseline among the different 4 groups. Administration of dapagliflozin was found to reduce HbA1c significantly after 6 months by 1 percentage point (p = 0.045) and showed a decreasing trend after 12 months of 1.5 percentage points (p = 0.062). Moreover, FBG was markedly reduced at 6 months and 9 months (p = 0.001 and p = 0.03, respectively). With further analysis of data from follow-up at 9 and 12 months, the mean HbA1c was reduced by greater values, 1.1 ± 1.4%, and 1.5 ± 2%, respectively; however, these values failed to reach statistical significance (p = 0.88 & p = 0.63, respectively). Likewise, the FBG level was reduced by larger values from 11.0 ± 2.0 mmol/L to 8.0 ± 1.8 mmol/L at 12 months, which could be of clinical importance although not statistically significant (p = 0.7). Notably, the HbA1c (Table 4) and FBG (Table 5) values within the 4 different treatment groups tended to decrease over the 12-month period but failed to reach statistical significance. Even the between-group differences in the HbA1c and FBG readings were statistically nonsignificant.

Discussion

The 2017 American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) comprehensive glycemic control algorithm has placed SGLT2 inhibitors before DPP4 inhibitors in the hierarchical order of recommended use as monotherapy as well as add-on therapy³⁹. This study was carried out to provide clinicians with research evidence on the use of dapagliflozin and its effectiveness in the management of T2-DM in combination with OHAs or insulin. The findings can be incorporated into their professional judgment and clinical decision-making.

Sufficient evidence demonstrates that many T2-DM patients do not achieve their glycemic goals⁴⁰. T2-DM is a progressive chronic disease, and over time, its treatment requires intensification. Dapagliflozin has a different mechanism of action. According to Fioretto *et al.*, dapagliflozin is completely insulin-independent and efficacious

as a single therapy or in combination with other agents⁴⁰. In another perspective, Vivian noted that dapagliflozin is recommended as an adjunct to diet and exercise to improve glycemic control⁴¹. In this retrospective study, information on the diet and physical activities of the patients was not available due to the retrospective nature of the study. The results of this study revealed that dapagliflozin significantly improved the glycemic control of Qatari type 2 diabetic patients when used in combination with standard therapy. The maximum HbA1c reduction of 1.5 percentage points was observed at 12 months, while a significant reduction of 1 percentage point was observed at 6 months from baseline. Fasting blood glucose was reduced started after 6 months of treatment by -2.9 mg/dl (25%). A study by Iijima and coworkers showed that dapagliflozin improved blood glucose levels significantly and worked well in poorly controlled T2-DM patients with glimepiride⁴². In our study, many patients were on glimepiride. Another study in Korea also demonstrated the significant addition of dapagliflozin to an existing drug regimen⁴³. The authors also indicated that the use of dapagliflozin as an add-on therapy could be a good alternative for patients who hesitate to use insulin therapy. Notably, the coadministered antidiabetic medications did not influence the reduction in either HbA1c or FBG. Our study was inconsistent with several other studies.

In a randomized study on T2-DM patients who were randomly given dapagliflozin, metformin extended release, or placebo for 12 weeks, List *et al.* found that at the end of the 12 weeks, dapagliflozin induced moderate glucosuria and a significant improvement in the glycemic index. In this study, they established that urinary excretion of 200–300 kcal/day (glucose) is associated with a reduction in HbA1c of 0.5 to 0.9 percentage points and in FBG by 13 to 16 mg/dL from baseline³⁷. Additionally, a group of studies evaluated dapagliflozin in combination with metformin slow/extended release^{32,37}, glimepiride^{32,38}, pioglitazone¹³, sitagliptin²¹, exenatide⁴⁴ and saxagliptin⁴⁵. These studies reported a significant reduction in HbA1c. Moreover, dapagliflozin maintained its efficacy in controlling type 2 diabetic patients on insulin and contributed to reducing their total daily insulin requirement by 50%²⁹.

The current study did not include dapagliflozin as a single agent. In a double-blinded, placebo-controlled phase-3 trial, Ferrannini *et al.* administered dapagliflozin as monotherapy to 485 patients inadequately controlled by diet and exercise, with HbA1c between 7.0 and 10%¹³. The patients were randomly assigned to receive placebo or dapagliflozin (2.5, 5, or 10 mg) once daily for 24 weeks. The reduction at the 24th week in HbA1c from the baseline was found to be -0.23 percentage points with the placebo and -0.58 , -0.77 , and -0.89 percentage points ($p = 0.0005$, $p = 0.0005$, and $p < 0.0001$ respectively) with 2.5, 5 and 10 mg dapagliflozin, respectively. Future studies in Qatar should examine the effectiveness of dapagliflozin as a single therapy.

Although this retrospective study has indicated several significant findings about dapagliflozin, it has some limitations. The patients' adherence to medication regimen, diet and lifestyle behaviors cannot be measured or followed. The sample size might be too small to confidently generalize the results to all populations who received this drug. Additionally, based on the sample selected, all patients included were Qataris; this fact again affects the generalizability of the results. Despite these limitations, the study has proven that dapagliflozin provides an additional benefit to the reduction in HbA1c and FBG among T2-DM patients in Qatar. Future research should focus on longitudinal follow-up studies with larger sample sizes and inclusion of other segments of the population.

Conclusion

Dapagliflozin significantly reduced the HbA1c level and FBG of type 2 diabetes patients as add-on therapy, regardless of the type of the coadministered OHA or insulin within a 6-month treatment period.

Methods

Study Design. This study is a retrospective before-and-after observational study conducted at Hamad General Hospital (HGH), a tertiary teaching hospital in Qatar. Patients were identified via automated reports generated through the pharmacy dispensing system. All consecutive patients who obtained dapagliflozin from HGH pharmacies during the 2-year time frame from 1 April 2013 until 30 April 2015 were evaluated based on the inclusion and exclusion criteria by reviewing the computerized patient profile system, i.e., eMR-viewer.

Ethical approval. The study proposal has been reviewed and approved by the Medical Research Center (MRC), an Institutional Review Board at Hamad Medical Corporation (the research ID number is # 15292/15). All methods were performed in accordance with the relevant guidelines and regulations of Hamad Medical Corporation. The ethics committee waived the need to obtain informed consent for this study.

Study population. All adult diabetic patients who had obtained dapagliflozin from HGH pharmacies during the period of 1 April 2013 to 30 April 2015 were included. Patients were excluded if they were younger than 18 years old, stopped their medication before completing one year, or had inadequate follow-up data.

Eighty-one patients were selected and followed up at 3, 6, 9 and 12 months. Patients were divided into four groups based on the most common antidiabetic medication combinations:

- (i) Group 1: Dapagliflozin + Metformin + Sulfonylureas (SUs) +/- DDP4i;
- (ii) Group 2: Dapagliflozin + Metformin + DDP4i +/- Insulin;
- (iii) Group 3: Dapagliflozin + Insulin + others; and
- (iv) Group 4: other combinations: Dapagliflozin + (Acarbose, Repaglinide, Liraglutide or Pioglitazone).

Study tool. The computerized patient medical profile was accessed to retrieve patient data after receiving ethical approval using a data collection sheet designed prior to the study.

Data collection procedure. Data regarding prescribed drugs were obtained from the pharmacy dispensing system. Demographic information and laboratory results were obtained from the patient's computerized profile (eMR-viewer). The period of treatment was determined from the first prescription dispensed from the pharmacy. The data collected included demographics, complete blood count, urea and electrolyte (baseline and follow-up), renal function (baseline and follow-up), duration of treatment, concomitant medications and any discontinuation of treatment.

Statistical analyses. Descriptive statistics were applied to present the demographics and baseline statistics. For the continuous variables, the mean (SD) or median (IQR) was reported. The categorical data were reported as frequencies and percentages. Data normality was evaluated by the Shapiro–Wilk test. Changes in the mean HbA1c and FBG over the four time points for the normally distributed data were analyzed using repeated measures ANOVA. The paired sample correlation test was carried out to identify points of significant change from baseline. A 95% confidence interval was reported, and a p value ≤ 0.05 was considered indicative of significance unless otherwise noted. Data analysis was performed using SPSS® version 23 (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp) in all analyses.

Ethical approval. This study was approved by the Institutional Review Board at the Medical Research Center of Hamad Medical Corporation.

Informed consent. Informed consent was not applicable; data were obtained from the medical records.

Data Availability

Data are available upon request.

References

- Ehrenkranz, R. R. L., Lewis, N. G., Kah, C. R. & Roth, J. Phlorizin: a review. *Diabetes Metab Res Rev.* **21**, 31–38 (2005).
- Vick, H., Diedrich, D. F. & Baumann, K. Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs. *Am J Physiol.* **224**, 552–57 (1973).
- Lee, W. S., Wells, R. G. & Hediger, M. A. The high-affinity NA/glucose cotransporter: re-evaluation and distribution of expression. *J Biol Chem.* **269**, 12032–39 (1994).
- U.S. Food and Drug Administration, “FDA Briefing Document, NDA 204042 Canagliflozin tablets. Advisory Committee Meeting, <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugs/AdvisoryCommittee/UCM334550.pdf>. [Accessed 28 September 2017] (2013).
- U.S. Food and Drug Administration: FDA briefing document: NDA 202293. Dapagliflozin tablets, 5 and 10 mg. Available from, <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/EndocrinologicandMetabolicDrugs/AdvisoryCommittee/ucm262994.pdf>. [Accessed 21 September 2017] (2011).
- Gerich, J. E. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. *Diabetic Medicine.* **27**(2), 136–42 (2010).
- DeFronzo, R. A., Davidson, J. A. & Del Prato, S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. *Diabetes, Obesity and Metabolism.* **14**(1), 5–14 (2012).
- Meng, W. *et al.* Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. *Journal of Medicinal Chemistry.* **51**(5), 1145–49 (2008).
- Han, S. *et al.* Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. *Diabetes.* **57**(6), 1723–29, <https://doi.org/10.2337/db07-1472> (2008).
- Bellamine, A. Dapagliflozin is a potent, competitive, selective and reversible inhibitor of SGLT2. BioMedical Transporters. Thun Switzerland. Available from, <http://www.bioparadigms.org/biomedical09/09.htm> (2009).
- Bailey, C. J., Iqbal, N., T'joen, C. & List, J. F. Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized controlled trial of low-dose range. *Diabetes, Obesity and Metabolism.* **14**(10), 951–59 (2012).
- Stenlöf, K. *et al.* Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. *Diabetes, Obesity and Metabolism.* **15**(4), 372–82 (2013).
- Rosenstock, J., Vico, M., Wei, L. I., Salsali, A. & List, J. F. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. *Diabetes Care.* **35**(7), 1473–78 (2012).
- Bergman, H. & Drury, D. R. The relationship of kidney function to the glucose utilization of the extra abdominal tissues. *American Journal of Physiology–Legacy Content.* **124**(2), 279–84 (1938).
- Bailey, C. J. *et al.* Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. *BMC Medicine.* **11**(1), 43 (2013).
- Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W. & List, J. F. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. *Diabetes Care.* **33**(10), 2217–24 (2010).
- Henry, R. R. *et al.* Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. *International Journal of Clinical Practice.* **66**(5), 446–56 (2012).
- Ji, L. *et al.* Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. *Clinical Therapeutics.* **36**(1), 84–100 (2014).
- Kaku, K. *et al.* Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. *Diabetes, Obesity and Metabolism.* **16**(11), 1102–10 (2014).
- Del Prato, S. *et al.* Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. *Diabetes, Obesity and Metabolism.* **17**(6), 581–90 (2015).
- Jabour, S. A., Hardy, E., Sugg, J. & Parikh, S. Study 10 Group. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. *Diabetes Care.* **37**(3), 740–50, <https://doi.org/10.2337/dc13-0467> (2014).
- Nauck, M. A. *et al.* Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. *Diabetes Care.* **34**(9), 2015–22 (2011).
- Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A. & List, J. F. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. *The Lancet.* **375**(9733), 2223–33 (2010).

24. Van Haalen, H. G. *et al.* Cost-effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. *Clinical Drug Investigation*. **34**(2), 135–46 (2014).
25. Wilding, J. P. *et al.* Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. *Annals of Internal Medicine*. **156**(6), 405–15 (2012).
26. Wilding, J. P., Woo, V., Rohwedder, K., Sugg, J. & Parikh, S. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. *Diabetes, Obesity and Metabolism*. **16**(2), 124–36 (2014).
27. Qumsieh, R. Y. *et al.* Identification of new alleles and the determination of alleles and genotypes frequencies at the CYP2D6 gene in Emiratis. *PLoS One*. **6**(12), e28943 (2011).
28. Risch, N., Burchard, E., Ziv, E. & Tang, H. Categorization of humans in biomedical research: genes, race and disease. *Genome Biology*. **3**(7), comment 2007-1 (2002).
29. Hjelm, K., Bard, K., Nyberg, P. & Apelqvist, J. Religious and cultural distance in beliefs about health and illness in women with diabetes mellitus of different origin living in Sweden. *International Journal of Nursing Studies*. **40**(6), 627–43 (2003).
30. Kridli, S. A. Health beliefs and practices among Arab women. *MNC: The American Journal of Maternal/Child Nursing*. **27**(3), 178–82 (2002).
31. Yang, W. *et al.* Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial. *J Diabetes*. 2018 Jul, **10**(7), 589–599, <https://doi.org/10.1111/1753-0407.12634>. (Epub 25 Jan 2018).
32. Christos, P. J. *et al.* Prevention of type II diabetes mellitus in Qatar: Who is at risk? *Qatar Med J*. **2014**(2), 70–81 (2014).
33. List, J. F., Woo, V., Morales, E., Tang, W. & Fiedorek, F. T. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. *Diabetes Care*. **32**(4), 650–57 (2009).
34. Mudaliar, S. *et al.* Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. *Diabetes Technology & Therapeutics*. **16**(3), 137–44 (2014).
35. Nauck, M. A. *et al.* Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. *Diabetes, Obesity and Metabolism*. **16**(11), 1111–20 (2014).
36. Langkilde, A. *et al.* Durability of dapagliflozin vs glipizide as add-on therapies in type 2 diabetes inadequately controlled on metformin: 4-year data. *In Diabetologia*. **56**, S374–S374 (2013).
37. Strojek, K. *et al.* Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. *Diabetes, Obesity and Metabolism*. **13**(10), 928–38 (2011).
38. Strojek, K. *et al.* Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycaemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. *Diabetes Ther*. **5**(1), 267–83 (2014).
39. Garber, A. J. *et al.* Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2017 Executive Summary. *Endocr Pract*. **23**(2), 207–38 (2017).
40. Fioretto, P., Giaccari, A. & Sesti, G. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. *Cardiovascular Diabetology* **14**, 142, <https://doi.org/10.1186/s12933-015-0297-x> (2015).
41. Vivian, E. M. Dapagliflozin: A new sodium–glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. *American Journal of Health-System Pharmacy* **72**(5), 361–372, <https://doi.org/10.2146/ajhp140168> (2015).
42. Iijima Y. *et al.* Effect of dapagliflozin in Japanese type 2 diabetes patients who have inadequate glycaemic control. *Diabetes Research and Clinical Practice* 2016, **120**, Supplement 1, Page S123, [https://doi.org/10.1016/S0168-8227\(16\)31231-1](https://doi.org/10.1016/S0168-8227(16)31231-1).
43. Jeon, H. J., Ku, E. J. & Oh, T. K. Dapagliflozin improves blood glucose in diabetes on triple oral hypoglycemic agents having inadequate glucose control. *Diabetes Research and Clinical Practice* **142**, 188–194, <https://doi.org/10.1016/j.diabres.2018.05.013> (2018).
44. Tatarikiewicz, K. *et al.* Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice. *Diabetes, Obesity and Metabolism*. **16**(4), 376–80 (2014).
45. Rosenstock, J., Mathieu, C., Chen, H., Garcia-Sanchez, R. & Saraiva, G. L. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. *Arch Endocrinol Metab*. **62**(4), 424–430, <https://doi.org/10.20945/2359-3997000000056> (2018).

Acknowledgements

The authors would like to thank the Hamad Medical Corporation for proving the research funding. This work was supported by the Medical Research Center of Hamad Medical Corporation [grant number 15292/15].

Author Contributions

R.A., Z.J., D.E. and H.A. conceived, planned and carried out the study. R.A., Z.J., D.E., H.A. and B.S. analyzed the data and contributed to the interpretation of the results. R.A., Z.J., D.E., H.A., B.S. and M.I.M.I. drafted and critically revised the manuscript. All authors provided final approval of the version to be published.

Additional Information

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019